SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
112 hedge funds and large institutions have $42.1M invested in SANGAMO THERAPEUTICS INC in 2025 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 17 reducing their positions, and 19 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 17
6% more capital invested
Capital invested by funds: $39.6M → $42.1M (+$2.52M)
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 114 → 112 (-2)
10.66% less ownership
Funds ownership: 31.41% → 20.75% (-11%)
16% less call options, than puts
Call options by funds: $989K | Put options by funds: $1.18M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.21M |
| 3 |
Jane Street
New York
|
+$1.19M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$888K |
| 5 |
Two Sigma Investments
New York
|
+$864K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
YAG
Yorkville Advisors Global
Mountainside,
New Jersey
|
-$11.9M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.59M |
| 3 |
Squarepoint
New York
|
-$338K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$178K |
| 5 |
BlackRock
New York
|
-$136K |
SGMO Hedge Fund Activity: Q3 2025 in Review
112 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q3 2025, worth a combined $42.1M — up 6.3% from $39.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SGMO and 18 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 39 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.8M. The largest seller was Yorkville Advisors Global, exiting entirely with an estimated $11.9M sold.
- 112 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q3 2025, down from 114 in Q2 2025.
- Funds reported $42.1M of SANGAMO THERAPEUTICS INC stock for Q3 2025, up 6.3% quarter-over-quarter.
- 18 funds opened new SANGAMO THERAPEUTICS INC positions in Q3 2025 and 19 closed out, a net change of -1 holder.
- The largest SANGAMO THERAPEUTICS INC buyer in Q3 2025 was Renaissance Technologies, an estimated $1.8M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q3 2025 was Yorkville Advisors Global, an estimated $11.9M sold.
Based on aggregated 13F filings for Q3 2025.